Background {#Sec1}
==========

The opportunistic human pathogen *Pseudomonas aeruginosa* is among the most common bacteria in health-care associated infections in Europe \[[@CR1]\]. Severe invasive disease, particularly with multidrug-resistant strains, involves high mortality rates \[[@CR2]\],\[[@CR3]\]. Early detection of carriers in high-risk patients is a crucial requirement to reduce spread of resistant strains and to administer appropriate empirical treatment in case the pathogen becomes invasive. On that account there is an essential need for a comprehensive knowledge of risk factors for nosocomial colonisation with resistant *P. aeruginosa*.

Prior exposures to antimicrobials or medical devices are common risk factors reported \[[@CR4]\]-\[[@CR6]\] but these studies are heterogeneous in terms of design, patient population and definition of multidrug resistance. The latter issue is likely to be improved due to the publication of an international expert proposal that defined bacterial resistance profiles on the basis of epidemiological relevant antimicrobial categories \[[@CR7]\]. The extensively drug-resistant *P. aeruginosa* (XDR-PA) that remains susceptible to a maximum of two classes of antimicrobials is clinically highly relevant due to the limited treatment options, its frequent isolation from ICU patients \[[@CR8]\] and the recently observed international spread \[[@CR9]\]. Risk factors have been primarily determined for invasive disease with XDR-PA \[[@CR10]\]-\[[@CR12]\] but predictors of patient colonisation have not yet been described.

In this study, we investigated potential risk factors for nosocomial XDR-PA colonisation in a haematological patient population. Consecutively, these results were used to construct a clinical risk score for the identification of patients at high risk for nosocomial XDR-PA colonisation, and the relative merit of this score as tool for efficient structuring of a local active screening culture policy in an endemic setting with XDR-PA was discussed.

Methods {#Sec2}
=======

Setting {#Sec3}
-------

The study was performed on the wards of the Department of Haematology in a 1500-bed tertiary teaching hospital in Tübingen, Germany. There are 80 beds at the department for the treatment of patients having various haematological-oncological conditions, such as leukaemia, lymphoma and multiple myeloma. Stem cell transplantations are regularly performed. One ward is an intensive care unit with single rooms. Routine screening for *P. aeruginosa* was carried out at admission and weekly thereafter. The screening involved rectal and pharyngeal swabs. Other diagnostic cultures were performed according to clinical status. The study is reported in conformity with the STrengthening the Reporting of OBservational studies in Epidemiology (STROBE) guidelines \[[@CR13]\]. The study has been approved by the local research ethics committee of the University of Tübingen (reference number: 659/2012R).

Study design, patients and definitions {#Sec4}
--------------------------------------

This matched case--control study was conducted from January 2010 to December 2013. Adult patients (≥ 18 years) hospitalised \> 48 h were considered eligible. Designation as case patient was based on the acquisition of a new hospital-acquired colonisation with an extensively drug-resistant *P. aeruginosa* (XDR-PA). XDR-PA were considered as hospital-acquired if they were diagnosed \>48 h after admission. XDR-PA was defined according to the CDC/ECDC criteria \[[@CR7]\]. The following antimicrobials were tested at our center: gentamicin, tobramycin, amikacin, piperacillin, piperacillin-tazobactam, ceftazidime, cefepime, ciprofloxacin, levofloxacin, meropenem, aztreonam, fosfomycin, and colistin. Intermediately susceptible isolates were considered resistant. The control group was composed of patients with either negative screening cultures for *P. aeruginosa* or of patients from whom a Non-XDR-*P. aeruginosa* was isolated. Controls were matched to cases for calendar time (quarters) and ward, and three controls were recruited for each case.

Time at risk was defined as time span between admission and new colonization with XDR-PA for cases, and as time span between admission and the last XDR-PA negative screening culture during hospitalisation for controls. According to the criteria mentioned above the minimum time at risk was three days. The primary exposure of interest was administration of antimicrobial agents. Furthermore, the length of administration (in antibiotic-days) was recorded as well as the total dose, converted into defined daily doses (DDD) conformable to the 2014 World Health Organization (WHO) anatomical therapeutic chemical (ATC) classification system \[[@CR14]\]. Investigated antibiotics were given per os and/or intravenously and included cephalosporins (cefuroxime, ceftazidime and cefepime), quinolones (levofloxacin and ciprofloxacin), meropenem, piperacillin-tazobactam, aminoglycosides (gentamicin, tobramycin and amikacin), cotrimoxazole, macrolides (erythromycin, clarithromycin and azithromycin), doxycycline, metronidazole, vancomycin, rifampicin, clindamycin, flucloxacillin, and aztreonam.

Patient files were reviewed by medically trained staff. Clinical data included time at risk; antibiotic treatment; age; sex; length of ICU stay, infectious diseases not caused by *P. aeruginosa* (IDNPA); baseline diseases; immunosuppression, such as neutropenia (\< 1000 cells/μl) and/or HIV and/or immunosuppressive chemotherapy within the previous two month (anti-inflammatory monoclonal antibody and anti-cancer drugs) and/or receipt of steroids (prednisolon ≥ 10 mg/daily or equivalent dose); Charlson comorbidity score at admission \[[@CR15]\]; simplified acute physiology score II (SAPS II) at admission (+ 48 h) \[[@CR16]\]; exposure to medical devices; baseline laboratory parameters during time at risk; and prior room occupation by a case patient (within 30 days and 6 weeks).

Laboratory-based testing {#Sec5}
------------------------

Material from rectal and pharyngeal swabs was inoculated on cetrimide agar (Cetrimide Agar Base 285420, Becton, Dickinson and Company, Heidelberg, Germany). Species identification was performed by a linear MALDI-TOF mass spectrometer (AXIMA Assurance, bioMérieux, Marcy l'Etoile, France), supplemented by Vitek 2 system identification (bioMérieux, Marcy l'Etoile, France). Antimicrobial susceptibility testing was carried out with the Vitek 2 system (bioMérieux, Marcy l'Etoile, France) and interpreted following EUCAST guidelines \[[@CR17]\].

The simultaneous detection of *bla*~VIM~ and *bla*~IMP~ genes was performed with a multiplex PCR according to a protocol described elsewhere \[[@CR18]\]. The VIM and IMP genes were entirely sequenced using the primer pairs IMP-A--IMP-B or VIM2004A-VIM2004B in combination with the class 1 integron primer pair 5CS and 3CS or alternatively VIM-2SQR \[[@CR18]\],\[[@CR19]\]. Multilocus sequence typing (MLST) was conducted according to the instructions on the *P. aeruginosa* website (<http://pubmlst.org/paeruginosa/>).

Statistical analysis {#Sec6}
--------------------

D'Agostino's K-squared test was employed to check continuous variables for normality. For skewed data, medians and interquartile ranges (IQR) were provided. However, median values and IQR were 0 for several continuous variables due to their skewed distribution. In such a case, the mean and range were presented. The chi-squared test or -- when appropriate -- the Fisher's exact test were performed to compare differences in proportion.

Odds ratios for XDR-PA colonisation were calculated for all variables with a minimum exposure of n = 10. Conditional logistic regression was used to calculate crude odds ratios for patient-related clinical variables. Any patient-related variable with a P-value of \< 0.1 in the univariate analysis was included in the Step I multivariate conditional logistic regression model and retained when the P-value was \< 0.05 using a backward stepwise elimination procedure. A Step II model was built by adding treatment-related variables (antibiotic use, length, total dose) one at a time to the final Step I model using conditional logistic regression. Length of administration and total dose of an antibiotic were investigated as quantitative variables to ensure that time- or dose-dependent effects are not missed. Treatment-related variables with a P-value \< 0.1 in the Step II model were subsequently added to the patient-related variables from the Step I model, forming a final Step III multivariate conditional logistic regression model. Variables were retained when the P-value was \< 0.05 using a backward stepwise elimination procedure as for the Step I model. The final Step III model contained patient- and treatment-related variables that were independent risk factors for an XDR-PA colonisation. Antibiotic use, length of use and total dose were investigated in separate Step III models to prevent biased results due to collinearity. Potential interactions were investigated using the likelihood ratio test.

For the construction of the clinical risk score (CRS) we have added up the adjusted odds ratios of all independent risk factors from the final Step III model and calculated the risk fraction according to their proportion of the total risk. Score points were allocated to each risk factor as per risk fraction value. The CRS is comprised of a total of 100 points. The discriminatory power of the CRS as well as a suitable cutoff to distinguish between patients with a high and low risk of being colonised with an XDR-PA was estimated by a receiver-operating characteristic (ROC) analysis.

A P-value \< 0.05 (two-sided) was deemed statistically significant. All analyses were carried out by using Stata version 12.0 (Stat Corp., College Station, TX, USA).

Results {#Sec7}
=======

A total of 124 patients (31 cases and 93 controls) were included in the risk factor analysis. Twenty-three case patients (74.2%) developed a rectal and eight case patients (25.8%) a pharyngeal XDR-PA colonisation. All XDR-PA strains were non-susceptible to piperacillin-tazobactam, ceftazidime, ciprofloxacin, meropenem, and aztreonam. Five XDR-PA (16.1%) were susceptible to aminoglycosides. A subset of 14 XDR-PA strains with identical susceptibility pattern was molecularly characterized. Twelve strains carried an IMP-8 gene and belonged to MSLT type 308 while two strains belonged to the MLST type 233 and haboured a VIM-2 gene, indicating the presence of at least two endemic strains in our setting. Sixteen control patients (17.2%) were colonised with a Non-XDR-PA during their hospital stay. The remaining 77 control patients (82.8%) were not colonized with *P. aeruginosa*. In-hospital mortality was 12.9% (4/31) for cases compared to 2.2% (2/93) for the controls (P = 0.016).

Baseline characteristics and crude odds ratios are presented in Table [1](#Tab1){ref-type="table"}. While a number of patient-related variables seemed to increase the risk for XDR-PA colonisation, only three variables turned out to be independent risk factors in the Step I multivariate model: presence of a central venous catheter, presence of an urinary catheter, and CRP during time at risk \> 10 mg/dl (Additional file [1](#MOESM1){ref-type="media"}: Table S1). Subsequently, the effect of treatment-related variables was investigated. Generally, case patients were more likely to have received antibiotics compared to controls (100% vs. 78.5%, P = 0.003). To gain more specific results, all treatment-related variables were added to the Step I model one at a time (Step II models). The administration of ciprofloxacin and ceftazidime as well as the administration of more than three different antibiotics during the time at risk were associated with the risk of XDR-PA colonisation in these Step II models (Table [1](#Tab1){ref-type="table"}). However, only the consumption of ciprofloxacin appeared to be an independent risk factor in the final Step III model (Table [2](#Tab2){ref-type="table"}). Of note, an increase of risk with a higher total dose or a longer administration of ciprofloxacin was not observed. The full list with results of treatment-related variables from all Step II models and the findings from all Step III models are shown in the Additional file [1](#MOESM1){ref-type="media"}: Table S2 and S3, respectively.Table 1**Baseline characteristics, comorbidities, laboratory and Step II treatment parameters of 124 patients: odds ratios for risk of XDR-PA colonisation**ParameterCases (n = 31)Controls (n = 93)Crude OR (95% CI)P-value*Basic parameters*Age, median (IQR), years56 (48--68)60 (51--70)0.9835 (0.9539 - 1.0141)^‡^0.28Female sex, %11 (35.5%)20 (21.5%)1.19 (0.53 - 2.65)0.68Admission from home, %26 (83.9%)83 (89.3%)0.61 (0.18 - 2.01)0.42Stay on ICU, %12 (38.7%)25 (26.9%)6.23 (1.16 - 33.4)0.024Length of ICU stay, mean (range), days10.58 (0--71)9.66 (0--80)1.0055 (0.9747 - 1.0374)^‡^0.73Time at risk \> 14 days, %19 (61.3%)39 (41.9%)2.54 (1.01 - 6.34)0.04IDNPA, %17 (54.8%)20 (21.5%)5.47 (1.95 - 15.37)0.0004*Comorbid conditions*Immune suppression, %30 (96.8%)79 (85%)5.35 (0.67 - 42.5)0.05Charlson Comorbidity Score, median (IQR)2 (2--4)2 (2--4)1.13 (0.91 - 1.41)0.28Diabetes, %5 (16.1%)16 (17.2%)0.92 (0.3 - 2.8)0.89Cardiovascular disease, %15 (48.4%)37 (39.8%)1.44 (0.62 - 3.3)0.4*Patient's clinical record*SAPS II, mean (range)27.97 (13--44)26.32 (6--51)1.0234 (0.9752 - 1.074)^‡^0.35Neutropenia (\<1000 cells/μl), %22 (71%)51 (54.8%)2.13 (0.86 - 5.31)0.095Length of Neutropenia, median (IQR), days9 (0--18)2 (0--16)1.0239 (0.9897 - 1.0592)^‡^0.17Non-invasive ventilation, %9 (29%)24 (25.8%)1.2 (0.46 - 3.13)0.71CVC, %21 (67.7%)40 (43%)3.48 (1.35 - 9)0.008Length of CVC, mean (range), days14.13 (0--59)11.13 (0--86)1.0155 (0.9867 - 1.0452)^‡^0.3Urinary catheter, %13 (41.9%)8 (8.6%)6.75 (2.38 - 19.17)0.0001Length of urinary catheter, mean (range), days4.03 (0--20)0.98 (0--23)1.1159 (1.0266 - 1.2129)^‡^0.005Room preoccupied by case (30 days), %4 (12.9%)7 (7.5%)1.46 (0.48 - 8.4)0.35Room preoccupied by case (6 weeks), %4 (12.9%)9 (9.7%)1.41 (0.38 - 5.22)0.61*Most pathological laboratory parameter during time at risk*White blood cell count, median (IQR), cells/μl1260 (330--3170)2060 (360--5720)0.99998 (0.99993 - 1.00004)^‡^0.73Neutrophils, median (IQR), cells/μl320 (20--1076)1090 (50--3383)0.9999 (0.9998 - 1)^‡^0.14Platelet count \< 50,000 cells/μl, %21 (67.7%)44 (47.3%)2.55 (1.04 - 6.28)0.04Creatinine, median (IQR), mg/dl1.1 (0.8 - 1.4)1 (0.8 - 1.2)1.27 (0.85 - 1.88)^‡^0.24CRP \> 10 mg/dl, %21 (67.7%)32 (34.4%)5.29 (1.88 - 14.89)0.0005*Step II treatment variables\*Cases (n = 31)Controls (n = 93)OR (95% CI)P-value*Ceftazidime use, %10 (32.3%)5 (5.4%)4.28 (0.74 - 24.77)0.09Ciprofloxacin use, %8 (25.8%)11 (11.8%)5.53 (1.11 - 27.53)0.025NDA \> 3, %20 (64.5%)27 (29%)4.35 (0.87 - 21.68)0.06^‡^Per 1 unit increase.\*All antibiotics with a P \< 0.1 in the Step II models are listed.XDR-PA, extensively drug-resistant *Pseudomonas aeruginosa*; IQR, interquartile range; ICU, intensive care unit; IDNPA, infectious diseases not caused by *Pseudomonas aeruginosa*; SAPS II, Simplified Acute Physiology Score II; CVC, central venous catheter; CRP, C-reactive protein; DDD, defined daily dose; NDA, number of different antibiotics during time at risk; 95% CI, 95% confidence interval.Table 2**Multivariate analysis (Step III): Odds ratios for risk of XDR-PA colonisation**VariableOR (95% CI)P-value*Clinical parameters\**Central venous catheter7.41 (1.98 - 27.68)0.0008Urinary catheter21.04 (3.67 - 120.57)\<0.0001CRP \> 10 mg/dl7.36 (1.81 - 29.85)0.0015*Treatment parameters -- drug*Ciprofloxacin use5.53 (1.11 - 27.53)0.025Ceftazidime use1.9 (0.22 - 16.43)0.56NDA \> 32.22 (0.36 - 13.65)0.39*Treatment parameters -- length of treatment*Ciprofloxacin, antibiotic-days1.01 (0.88 - 1.16)^‡^0.88*Treatment parameters -- total dosage*Ciprofloxacin total dose, DDD1.01 (0.87 - 1.17)^‡^0.91\*The results shown are based on the final model with the treatment-related variables for use of antibiotics.^‡^Per 1 unit increase.XDR-PA, extensively drug-resistant *Pseudomonas aeruginosa*; CRP, C-reactive protein; NDA, number of different antibiotics during time at risk; DDD, defined daily dose; 95% CI, 95% confidence interval.

The four independent risk factors were used to build a clinical risk score. The CRS consists of 100 points, and points were allocated according to the risk fraction of each factor (Table [3](#Tab3){ref-type="table"}). The presence of a urinary catheter was given slightly lower points than indicated by rounding the risk fraction due to the large 95% confidence interval in the final Step III model. The discriminatory power of the CRS was assessed by a ROC analysis. The area under the ROC curve (AUC) was 0.83 (95% confidence interval: 0.75 -- 0.91). A cutoff was chosen to differentiate the patients in those with a higher risk of XDR-PA colonisation (high risk group) and those with a lower risk (low risk group). Patients with a CRS ≥ 36 points have an odds of XDR-PA colonisation of 1.29, thus associated with the high risk group. On the other hand, patients with a CRS \< 36 points have an odds of XDR-PA colonisation of only 0.12 and thus belong with the low risk group. The risk of being a case is approximately fourteen times greater in the high risk group (conditional logistic regression, OR 14; 95% confidence interval: 4.1 -- 47.9; P \< 0.0001).Table 3**Buildup and structure of the clinical risk score**Score variableOR (step III)Risk fraction (%)PointsCentral venous catheter7.4117.9%18Urinary catheter21.0450.9%50CRP \> 10 md/dl7.3617.8%18Ciprofloxacin use5.5313.4%14XDR-PA, extensively drug-resistant *Pseudomonas aeruginosa*; CRP, C-reactive protein.

Discussion {#Sec8}
==========

Our study aimed to investigate potential risk factors of XDR-PA colonisation in a haematological patient population and to set up a clinical risk score to differentiate between patients with a higher and lower risk of XDR-PA acquisition.

The primary exposure of interest was the administration of antimicrobial agents as this is one of the major concerns for the acquisition of resistant strains. We found the use of ciprofloxacin to be an independent risk factor. Ciprofloxacin is used in our institution for prophylaxis in neutropenic patients. The total dose and time span of administration did not play a role. These results are in line with previous reports for multidrug-resistant *P. aeruginosa* (MDR-PA) acquisition in different settings \[[@CR5]\],\[[@CR20]\],\[[@CR21]\]. In contrast, ceftazidime administration was not independently associated with XDR-PA colonisation despite a tendency of being a risk factor in the corresponding Step II model (OR 4.28, P = 0.09). The hospital-wide use of cephalosporins was previously correlated with the incidence of XDR-PA in a multivariate time series analysis and is thus likely to exist for the hospital setting rather than for the Department of Haematology alone \[[@CR22]\]. However, an independent association between ceftazidime administration and XDR-PA colonisation in our haematological patient population cannot be excluded due to limitations in the study power of the present investigation. Moreover, the inclusion of patients with Non-XDR-PA colonisation into the control group might have led to a selection bias according to Harris et al. \[[@CR23]\],\[[@CR24]\]. In the present study, this should have caused only a minor bias if at all due to the low proportion of these patients among the control group (17.2%). Regarding these patients as a part of the source population from which case patients could arise prevents a general selection bias and retains the internal and external validity of our study \[[@CR25]\].

Another interesting discovery was an increase in risk when more than three different antibiotics were administered during hospitalisation (OR 4.35, P = 0.06). Although this result was not confirmed in the final Step III model and must thus be interpreted with caution, it suggests that the use of different antibiotics could ease an at least temporary establishment of XDR-PA, possibly due to a broader and more destructive impact on the gut or respiratory tract flora compared to treatment with fewer agents.

Surprisingly, a relatively low risk fraction for ciprofloxacin use (13.4%) was observed when compared with independent patient-related risk factors. Primarily the use of medical devices had a major impact on the risk of XDR-PA colonisation (central venous catheter and urinary catheter; joint risk fraction 68.8%, Table [3](#Tab3){ref-type="table"}). A recent meta-analysis has shown that medical devices are leading risk factors for the acquisition of carbapenem-resistant *P. aeruginosa* \[[@CR6]\]. This indicates that invasive procedures like insertion of catheters by medical personnel can contribute to the spread and sustainment of resistance in the hospital. Interestingly, in contrast to a previous report we have not seen that prior occupation of a room with a case patient has increased the risk for subsequent patients \[[@CR26]\]. This supports the hypothesis that medical personnel represent -- in terms of XDR-PA acquisition - a greater risk for the patient than environmental contamination. However, the results of the univariate analysis suggest that with every urinary catheter day evolves a stepwise increase in the odds ratio for XDR-PA colonisation of approximately 11% (P = 0.005), indicating that having a urinary catheter could lead to a patient behaviour, special care or exposure to unknown environmental factors that further increase the acquisition risk.

A C-reactive protein \> 10 mg/dl was identified as another independent and patient-related risk factor. It is not within the scope of our study to give a comprehensive explanation for this finding, but it can be speculated whether this reflects a pro-inflammatory situation or a concomitant infectious disease that impairs the protective mucosal barrier and could thus promote a more effective adherence of the pathogen.

We have found a significantly higher in-hospital mortality among case patients compared to controls (12.9% versus 2.2%, P = 0.016). But this results need to be interpreted with caution since we have not directly investigated the impact of XDR-PA colonisation on mortality. However, it strengthens the findings of a previous study in our setting where mortality was significantly different between patients with bloodstream infection due to metallo-β-lactamase (MBL) producing *P. aeruginosa* or Non-MBL producing *P. aeruginosa* ( 61% versus 34%) \[[@CR27]\]. Additionally, Tacconelli et al. have reported that 9% of patients with a new hospital-acquired colonisation with an antibiotic resistant bacterium developed subsequently an infection due to the same pathogen \[[@CR4]\]. Thus, identifying the patients' carrier status could improve chances to choose an appropriate empirical treatment when necessary, particularly in an institution with a relevant incidence of multidrug-resistant pathogens.

The weekly rectal and pharyngeal screening for *P. aeruginosa* was introduced in our Department of Haematology in response to an increase in the incidence of MDR- and XDR-PA. It is a reasonable assumption that active screening cultures (ASC) facilitate an early detection of carrier status that should be followed by appropriate infection control measures when an MDR- or XDR-PA is found. On the other hand, there is no evidence at the moment that ASC is effective in decreasing the incidence of targeted organisms in the long-term, and thus it is only recommended as an additional procedure \[[@CR28]\]. However, ASC might be more effective if the screening strategy is adapted to the local setting. The differentiation into low and high risk groups according to local risk factors and a subsequent modification of the screening frequency for both groups could be an approach to efficiently allocate resources and focus on the patients who could benefit the most from ASC. Our CRS exhibits a high discriminatory power (AUC = 0.83) with an approximately fourteen times greater risk for nosocomial colonisation with XDR-PA in the high risk group. An example of how a weekly screening strategy for all patients can be adjusted to the local setting by using such a CRS is shown in Figure [1](#Fig1){ref-type="fig"}.Figure 1**Flow chart for a locally adapted active screening culture (ASC) strategy.** Patients once classified as high risk patients for XDR-PA colonisation remain their status until discharge und are screened twice a week.

We are aware that our study has several limitations. The CRS is derived from the odds ratios of significant risk factors in our study population. Its true performance would need to be evaluated on another patient cohort in the same setting, preferably with a prospective design. In addition, the study power could have been too low to reveal moderately associated risk factors. Also, this is a single center study and results are usually not transferable to other settings. However, it must be stated that even results of multicenter studies as well as recommendations from generally accepted guidelines can turn out as inappropriate. An example are the results from a research group in eastern China who found the American Thoracic Society (AST) guidelines criteria not reliable for the prediction of multidrug-resistant organisms in their hospital \[[@CR29]\]. For this reason, we recommend for any setting i) to identify the locally most common resistant pathogens, ii) to investigate the most relevant risk factors for acquisition, and iii) to adapt the local infection control policy according to the observed risk factors, for instance in the context of a local CRS as suggested by our work.

Conclusion {#Sec9}
==========

We found ciprofloxacin use as well as patient-related factors to independently increase the risk for XDR-PA colonisation. The results indicate that unnecessary administration of antibiotics, specifically ciprofloxacin should be avoided and that a high infection control standard must be accomplished when medical devices are used. Additionally, a switch to alternative regimes for prophylaxis in neutropenic patients is a recommendable option. Identified risk factors can be applied to adapt local screening strategies for an early detection of resistant organisms with a subsequently more efficient prevention of their spread and administration of appropriate empirical treatment if necessary.
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